Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

A Pfizer Covid booster vaccination gave a fit 54-year-old chronic pain, NHS doctors found. Larry Lowe, from Omagh in Northern ...

Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.